![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 24, 2024
Details:
Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 23, 2024
Details:
Through this merger, Sun Pharma will gain access to Taro's pipelines, enabling further commercialization in the market, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 17, 2024
Details:
Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obstructive sleep apnoea.
Lead Product(s): Acetazolamide,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Incannex Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 18, 2023
Details:
Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (eg, some types of glaucoma), in the treatment of certain convulsive disorders and in the promotion of diuresis in instances of abnormal fluid retention.
Lead Product(s): Acetazolamide
Therapeutic Area: Ophthalmology Product Name: Diamox-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
All doses of IHL-42X (Dronabinol) reduced AHI in patients with sleep apnoea compared to baseline. This reduction was substantially greater than observed for placebo.
Lead Product(s): Tetrahydrocannabinol,Acetazolamide
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
IHL-42X (dronabinol) is a fixed-dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea (‘OSA’) in adults.
Lead Product(s): Tetrahydrocannabinol,Acetazolamide
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
20% of participants experienced a reduction in AHI of greater than 80% relative to baseline during at least one treatment period of one dose strength of IHL-42X and, average of low, mid, and high-dose IHL-42X reduced AHI in trial participants by 44.4%, compared to baseline.
Lead Product(s): Tetrahydrocannabinol,Acetazolamide
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022